Suppr超能文献

低促性腺激素性性腺功能减退患者的抗苗勒管激素

Antimüllerian hormone in patients with hypogonadotropic hypogonadism.

作者信息

Young J, Rey R, Couzinet B, Chanson P, Josso N, Schaison G

机构信息

Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre, Kremlin Bicêtre, France.

出版信息

J Clin Endocrinol Metab. 1999 Aug;84(8):2696-9. doi: 10.1210/jcem.84.8.5972.

Abstract

Antimullerian hormone (AMH) is produced by immature Sertoli cells until pubertal maturation. At puberty, elevation of serum testosterone correlates with a decrease in serum AMH. To further investigate the hormonal control of AMH secretion, serum AMH levels were measured in 20 normal men (20-60 yr), in 12 patients (19-30 yr) with congenital hypogonadotropic hypogonadism (CHH), and in 18 patients (19-65 yr) with acquired hypogonadotropic hypogonadism (AHH) either untreated or during testosterone or human chorionic gonadotropin (hCG) therapy. Mean serum AMH levels in normal adult men were low (20+/-4.9 pmol/L). In untreated CHH patients, mean serum AMH levels were significantly higher than in normal men (292+/-86 pmol/L, P < 0.001) and were similar to those previously reported in prepubertal boys. In men with AHH, mean serum AMH levels were also significantly increased (107+/-50 pmol/L; P < 0.01) when compared with healthy men but were less than in men with CHH. In addition, in 10 patients treated for prostate cancer, a modest but significant increase of serum AMH (from 11.4 +/-5.7 pmol/L to 49+/-9.9 pmol/L; P < 0.01) was observed 12 months after suppression of the gonadal axis with the GnRH agonist Triptorelin (3.75 mg IM once a month). Plasma testosterone (T) and serum AMH levels were measured at baseline and at 3 and 6 months in 10 HH patients (6 CHH and 4 AHH) treated with hCG (1500 IU/twice weekly for 6 months) and in 8 HH (4 CHH and 4 AHH) patients treated with T (T enanthate 250 mg/3 weeks for 6 months). hCG treatment induced an increase of plasma T (from 1.0+/-0.7 to 11+/-2.4 and 19+/-4.8 nmol/L, at 3 and 6 months respectively) associated with a dramatic decrease of serum AMH (from 314+/-93 to 56+/-30 and 17+/-4.3 pmol/L). The similar increase in plasma T levels (from 1.4+/-1.0 to 15.6+/-4.2 and 23+/-6.2 ng/mL) obtained with exogenous T induced a lesser decrease of serum AMH (from 221+/-107 pmol/L to 114+/-50 and 66+/-17 pmol/L, at 3 and 6 months respectively). In conclusion, high plasma AMH levels in CHH patients are related to the absence of pubertal maturation of Sertoli cells. The high AMH levels in AHH and its increase after Triptorelin-induced gonadotropin deficiency suggest that the suppression of AMH is a reversible phenomenon. Finally, the inhibition of AMH production by Sertoli cells is induced by intratesticular T.

摘要

抗苗勒管激素(AMH)由未成熟的支持细胞分泌,直至青春期成熟。青春期时,血清睾酮水平升高与血清AMH水平降低相关。为进一步研究AMH分泌的激素调控机制,我们检测了20名正常男性(20 - 60岁)、12例先天性低促性腺激素性腺功能减退(CHH)患者(19 - 30岁)以及18例获得性低促性腺激素性腺功能减退(AHH)患者(19 - 65岁)未治疗时、睾酮或人绒毛膜促性腺激素(hCG)治疗期间的血清AMH水平。正常成年男性的平均血清AMH水平较低(20±4.9 pmol/L)。未治疗的CHH患者,其平均血清AMH水平显著高于正常男性(292±86 pmol/L,P < 0.001),与之前报道的青春期前男孩相似。AHH男性患者的平均血清AMH水平与健康男性相比也显著升高(107±50 pmol/L;P < 0.01),但低于CHH患者。此外,在10例接受前列腺癌治疗的患者中,使用促性腺激素释放激素(GnRH)激动剂曲普瑞林(3.75 mg,每月皮下注射1次)抑制性腺轴12个月后,血清AMH水平出现适度但显著的升高(从11.4±5.7 pmol/L升至49±9.9 pmol/L;P < 0.01)。在10例接受hCG治疗(1500 IU,每周2次,共6个月)的HH患者(6例CHH和4例AHH)以及8例接受睾酮治疗(庚酸睾酮250 mg,每3周1次注射,共6个月)的HH患者(4例CHH和AHH)中,分别在基线、3个月和6个月时检测血浆睾酮(T)和血清AMH水平。hCG治疗使血浆T水平升高(分别在3个月和6个月时从1.0±0.7升至11±2.4和19±4.8 nmol/L),同时血清AMH水平显著降低(从314±93降至56±30和17±4.3 pmol/L)。外源性睾酮使血浆T水平出现类似升高(从1.4±1.0升至15.6±4.2和23±6.2 ng/mL),血清AMH水平的降低幅度较小(分别在3个月和6个月时从221±107降至114±50和66±17 pmol/L)。总之,CHH患者血浆AMH水平升高与支持细胞青春期未成熟有关。AHH患者AMH水平升高以及曲普瑞林诱导性腺功能减退后AMH水平升高表明,AMH的抑制是一种可逆现象。最后,睾丸内T可诱导支持细胞抑制AMH的产生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验